Regional astrocyte dysregulation and altered glymphatic‐related markers in Alzheimer’s disease frontal cortex

by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia

Abstract INTRODUCTION Astrocyte dysfunction is central to Alzheimer’s disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin-4 (AQP4) and glial fibrillary acidic protein (GFAP) in post-mortem frontal cortex of AD...

Design and Efficacy of Localized Non-Pharmacological Cognitive Materials: A Participatory Card-Game Intervention for Older Adults With Dementia in Taiwan

by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia

Dementia, Ahead of Print. Non-pharmacological interventions are widely recognised as essential components of dementia care. However, many cognitive activities lack cultural relevance and are difficult to integrate into everyday care practice. Design-driven approaches...

Proteomic signatures of protected APOE ε4 carriers reveal causal pathways associated with delayed Alzheimer’s disease onset

by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia

Abstract INTRODUCTION APOE ε4 is the strongest common genetic risk factor for Alzheimer’s disease (AD), yet many carriers remain cognitively unimpaired into late life. We tested whether protected ε4-first plasma proteomics could identify proteins associated with...

Correction to “White matter hyperintensities are associated with locus coeruleus atrophy and astrocytic β2‐adrenergic receptor expression”

by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia

Alzheimer’s &Dementia, Volume 22, Issue 8, August 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | August 13, 2026 Neuro-Dementia Previous...

Long‐term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer’s disease: Results from AB1601 phase 2 extension study

by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia

Abstract INTRODUCTION ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer’s disease (AD). A 24-month randomized, placebo-controlled phase 2 study (Part A) showed favorable safety and robust...

Social engagement and brain structure‐informed cognitive domain trajectories in older adults: The National Health and Aging Trends Study

by Clinical Neuropsychologist Online | Wednesday, August 12, 2026 | Dementia

Abstract INTRODUCTION Cognitive decline may emerge in specific domains before overt dementia, yet domain-specific cognitive benefits of social engagement remain unclear. METHODS Using National Health and Aging Trends Study (NHATS) data (2011–2019) from 6,084...